Novel inhalable nano-based/microparticles for enhanced sustained pulmonary delivery of remdesivir - A patient malleable treatment for coronaviruses infection: In vitro aerosolization, cytotoxicity assays and antiviral activity studies
Shahinaze A. Fouad,Fady A. Malaak,Mahmoud H. Teaima,Samia Omar,Omnia Kutkat,Sammar Fathy Elhabal,Mohamed El-Nabarawi
DOI: https://doi.org/10.1016/j.jddst.2024.106196
IF: 5
2024-09-21
Journal of Drug Delivery Science and Technology
Abstract:Highlights • Remdesivir (RDV) was effectively loaded into novel nanosuspension systems comprising polycaprolactone and pluronic® F-127. • Nano-based/microparticles were successfully prepared by co-spray drying the optimized RDV loaded nanosuspension with hyaluronic acid and mannitol, producing dry powder for inhalation; OLN-microparticles. • OLN-microparticles displayed efficacious aerosolization features for targeted pulmonary delivery of RDV showing emitted fraction (EF) ∼ 97.46 ± 1.70 %, respirable particle fraction (RPF) ∼ 53.77 ± 0.2 %, effective inhalation index (EII) ∼ 72.39 ± 1.40 %, and mass median aerodynamic diameter (MMAD) ∼ 2.25 ± 0.01 μm. • OLN-microparticles showed satisfactory cytotoxicity (CC 50 ∼ 252.0 μg/mL), and antiviral activity (IC 50 ∼ 13.08 μg/mL), with 1.3 fold increase in safety index (SI) compared to raw RDV ( p = 0.0064). • Hence, OLN-nicroparticles represents a novel sustained drug delivery system for RDV, avoiding the limitations accompanied with its IV administration. It is considered a promising drug delivery system for outpatients and their healthcare givers, as it offers an easy and adaptable delivery of RDV in case of coraonaviruses infection, without the need for hospitalization. Remdesivir (RDV) is an antiviral used in potential treatment of SARS-COV-2 infection during the COVID-19 pandemic worldwide. However, it is still limited to IV administration for hospitalized patients. Therefore, we report herein successful development of RDV-loaded nanosuspensions (NS) using polycaprolactone and pluronic® F127, for the first time. The optimized RDV-NS was further loaded into inhalable nano-based/microparticles (OLN-microparticles) via co-spray drying with hyaluronic acid and mannitol. OLN-microparticles exhibited high yield value ∼80.56 %, with satisfactory entrapment efficiency and drug loading percent ∼97.27 ± 1.84 % and 3.92 ± 0.07 %, respectively. Carr's index was equal to 22.7 ± 11.67 % indicating good flowability properties. Scanning electron microscopic analysis showed spherical-shaped particles. Transmission electron microscope demonstrated grape-shaped clumps surface porosity. OLN-microparticles exhibited excellent aerodynamic features including; emitted fraction ∼97.46 ± 1.70 %, respirable particle fraction 53.77 ± 0.2 %, effective inhalation index 72.39 ± 1.40 %, and mass median aerodynamic diameter 2.25 ± 0.01 μm. Compared to plain RDV, OLN-microparticles showed significantly enhanced sustained release ( p < 0.0001) with 1.5 and 1.9 fold increase at 24 and 48 h, respectively in Gamble's solution. OLN-microparticles also showed favorable cytotoxic profile with CC 50 ∼ 252.0 μg/mL, inhibitory concentration (IC 50 ) 13.08 μg/mL, and safety index (SI) 19.26 which is 1.3 fold higher compared to plain RDV. The Optimal release profile of OLN-microparticles enabled controlled and sustained release with enhanced cellular uptake. Hence, OLN-microparticles represented an efficient alternative form of dry powder for inhalation for deep and targeted pulmonary delivery of RDV, outweighing limitations accompanied with IV administration. It can provide self-administered and malleable access of treatment for SARS-COV-2 infected patients. Graphical abstract Download: Download high-res image (319KB) Download: Download full-size image
pharmacology & pharmacy